Karen Massey, who joined Argenx in March 2023 as Chief Operating Officer, has been promoted to CEO. She succeeds Tim Van Hauwermeiren, who founded the company and has been the CEO since 2008. Her appointment follows shareholder approval of her addition to the board of directors as an executive member. Tim Van Hauwermeiren has been appointed chairman of the board of directors, effective immediately, after transitioning to a non-executive director.
Quorum and Voting
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The annual general meeting saw 90.9% of the share capital represented. All items on the agenda received the required majority of favorable votes, including the appointments of Karen Massey as CEO and Tim Van Hauwermeiren as chairman.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 2 854 millions de dollars
Quarterly revenue: 2 854 millions de dollars
Revenue growth: 58,5 %
Net income: 838 millions de dollars
Free cash flow: 700 millions de dollars
Risks mentioned
Étude sur les myosites auto-immunes attendue au T3 2026, un jalon clé pour l'expansion de VYVGART.
Les dépenses d'exploitation continuent d'augmenter, totalisant 2,0 milliard USD pour le semestre.
Opportunities identified
VYVGART a été lancé avec succès, étendant l'accès aux patients.
Au 31 décembre 2026, argenx prévoit de disposer de dix molécules en développement clinique.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
